Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-010 in Atopic Dermatitis and Psoriasis
NCT03381625Phase 2Completed
- Sponsor
- BioMimetix
- Start
- Jan 2018
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) and psoriasis comparing BMX-010 0.03% with Placebo (2 arms). Primary endpoints: Systemic Adverse Events Caused by BMX-010 on Atopic Dermatitis Lesions, Systemic Adverse Events Caused by BMX-010 on Psoriasis Lesions and 1 more. Started Jan 2018; status: completed.
02
Drugs
BMX-010
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT03381625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381625.